• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

靶向多发性骨髓瘤中的自噬

Targeting autophagy in multiple myeloma.

作者信息

Yun Zhuang, Zhichao Jin, Hao Yao, Ou Ji, Ran Yang, Wen Dong, Qun Shen

机构信息

Hematology Department, The First Affiliated Hospital of Nanjing University of Chinese Medicine, Hanzhong Road No.155, Baixia District, Nanjing 210029, Jiangsu Province, China; Nanjing University of Traditional Chinese Medicine, Xianlin Avenue No.138, Qixia District, Nanjing 210046, Jiangsu Province, China.

Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, No. 5 Beixiange, Xicheng District, Beijing 100053, China.

出版信息

Leuk Res. 2017 Aug;59:97-104. doi: 10.1016/j.leukres.2017.06.002. Epub 2017 Jun 3.

DOI:10.1016/j.leukres.2017.06.002
PMID:28599191
Abstract

Autophagy plays an important role in plasma cell ontogeny and in the pathophysiology of multiple myeloma. Autophagy is usually considered a pro-survival mechanism, and cooperates with the ubiquitin proteasome system in maintaining the homeostasis of myeloma cells by degrading excessive and misfolded proteins for energy recycling. Therefore, the inhibition of autophagy could effectively induce death in myeloma cells, and could synergize with proteasome inhibitors. However, the excessive activation of autophagy could also lead to the extreme degradation of the organelles that induce autophagic cell death. Hence, the activation of autophagic cell death might also represent a promising approach for treating myeloma. Recent studies have demonstrated that autophagy also mediates drug resistance in myeloma cells and the complications of myeloma, while the inhibition of autophagy may reverse the response to drugs. In this study, we have mainly reviewed recent research on autophagy in relationship to the therapeutic effect, the reversal of drug resistance, and the mediation of complications.

摘要

自噬在浆细胞发生及多发性骨髓瘤的病理生理学中发挥着重要作用。自噬通常被认为是一种促生存机制,它与泛素蛋白酶体系统协同作用,通过降解过量及错误折叠的蛋白质以进行能量循环,从而维持骨髓瘤细胞的稳态。因此,抑制自噬可有效诱导骨髓瘤细胞死亡,并可与蛋白酶体抑制剂产生协同作用。然而,自噬的过度激活也可能导致细胞器的过度降解,进而诱导自噬性细胞死亡。因此,激活自噬性细胞死亡也可能是治疗骨髓瘤的一种有前景的方法。最近的研究表明,自噬还介导骨髓瘤细胞的耐药性及骨髓瘤的并发症,而抑制自噬可能会逆转对药物的反应。在本研究中,我们主要综述了近期关于自噬与治疗效果、耐药性逆转及并发症介导相关的研究。

相似文献

1
Targeting autophagy in multiple myeloma.靶向多发性骨髓瘤中的自噬
Leuk Res. 2017 Aug;59:97-104. doi: 10.1016/j.leukres.2017.06.002. Epub 2017 Jun 3.
2
A plastic SQSTM1/p62-dependent autophagic reserve maintains proteostasis and determines proteasome inhibitor susceptibility in multiple myeloma cells.一种依赖于SQSTM1/p62的可塑性自噬储备维持蛋白质稳态并决定多发性骨髓瘤细胞对蛋白酶体抑制剂的敏感性。
Autophagy. 2015;11(7):1161-78. doi: 10.1080/15548627.2015.1052928.
3
The Proteasome Inhibitor Bortezomib Maintains Osteocyte Viability in Multiple Myeloma Patients by Reducing Both Apoptosis and Autophagy: A New Function for Proteasome Inhibitors.蛋白酶体抑制剂硼替佐米通过减少凋亡和自噬维持多发性骨髓瘤患者骨细胞的活力:蛋白酶体抑制剂的新功能
J Bone Miner Res. 2016 Apr;31(4):815-27. doi: 10.1002/jbmr.2741. Epub 2015 Dec 14.
4
MARCKS inhibition cooperates with autophagy antagonists to potentiate the effect of standard therapy against drug-resistant multiple myeloma.MARCKS 抑制与自噬拮抗剂协同作用,增强标准疗法对耐药性多发性骨髓瘤的疗效。
Cancer Lett. 2020 Jun 28;480:29-38. doi: 10.1016/j.canlet.2020.03.020. Epub 2020 Mar 24.
5
KLF4-SQSTM1/p62-associated prosurvival autophagy contributes to carfilzomib resistance in multiple myeloma models.KLF4-SQSTM1/p62相关的促生存自噬在多发性骨髓瘤模型中导致卡非佐米耐药。
Oncotarget. 2015 Jun 20;6(17):14814-31. doi: 10.18632/oncotarget.4530.
6
Targeting autophagy increases the efficacy of proteasome inhibitor treatment in multiple myeloma by induction of apoptosis and activation of JNK.靶向自噬通过诱导细胞凋亡和激活 JNK 增加蛋白酶体抑制剂治疗多发性骨髓瘤的疗效。
BMC Cancer. 2022 Jul 6;22(1):735. doi: 10.1186/s12885-022-09775-y.
7
Curcusone D, a novel ubiquitin-proteasome pathway inhibitor via ROS-induced DUB inhibition, is synergistic with bortezomib against multiple myeloma cell growth.姜黄素D是一种通过活性氧诱导的去泛素化酶抑制作用的新型泛素-蛋白酶体途径抑制剂,与硼替佐米联合使用对多发性骨髓瘤细胞生长具有协同作用。
Biochim Biophys Acta. 2014 Jun;1840(6):2004-13. doi: 10.1016/j.bbagen.2014.02.006. Epub 2014 Feb 15.
8
Different Strategies to Overcome Resistance to Proteasome Inhibitors-A Summary 20 Years after Their Introduction.克服蛋白酶体抑制剂耐药性的不同策略——引入 20 年后的总结。
Int J Mol Sci. 2024 Aug 16;25(16):8949. doi: 10.3390/ijms25168949.
9
Control of autophagic cell death by caspase-10 in multiple myeloma.胱天蛋白酶-10 调控多发性骨髓瘤细胞自噬性细胞死亡。
Cancer Cell. 2013 Apr 15;23(4):435-49. doi: 10.1016/j.ccr.2013.02.017. Epub 2013 Mar 28.
10
Stew in its Own Juice: Protein Homeostasis Machinery Inhibition Reduces Cell Viability in Multiple Myeloma Cell Lines.原汁炖煮:蛋白动态平衡机制抑制降低多发性骨髓瘤细胞系的细胞活力。
Curr Mol Med. 2019;19(2):112-119. doi: 10.2174/1566524019666190305134441.

引用本文的文献

1
Deciphering MARCH5's impact on multiple myeloma: insights into autophagy regulation and AKT-FOXO3 signaling.解读MARCH5对多发性骨髓瘤的影响:对自噬调节和AKT-FOXO3信号传导的见解
Blood Neoplasia. 2024 Oct 12;1(4):100046. doi: 10.1016/j.bneo.2024.100046. eCollection 2024 Dec.
2
Prognostic model and immune-infiltrating cell landscape based on differentially expressed autophagy-related genes in TP53-mutated multiple myeloma.基于TP53突变型多发性骨髓瘤中差异表达的自噬相关基因的预后模型及免疫浸润细胞图谱
Arch Med Sci. 2021 Jul 27;20(5):1619-1630. doi: 10.5114/aoms/140293. eCollection 2024.
3
Polymorphisms within autophagy-related genes as susceptibility biomarkers for pancreatic cancer: A meta-analysis of three large European cohorts and functional characterization.
自噬相关基因多态性作为胰腺癌易感性生物标志物的研究:三个大型欧洲队列的荟萃分析及功能特征分析。
Int J Cancer. 2025 Jan 15;156(2):339-352. doi: 10.1002/ijc.35196. Epub 2024 Sep 25.
4
Synergistic induction of mitotic pyroptosis and tumor remission by inhibiting proteasome and WEE family kinases.通过抑制蛋白酶体和 WEE 家族激酶诱导有丝分裂细胞焦亡和肿瘤消退的协同作用。
Signal Transduct Target Ther. 2024 Jul 12;9(1):181. doi: 10.1038/s41392-024-01896-z.
5
Targeting mTOR signaling pathways in multiple myeloma: biology and implication for therapy.靶向多发性骨髓瘤中的 mTOR 信号通路:生物学及治疗意义。
Cell Commun Signal. 2024 Jun 11;22(1):320. doi: 10.1186/s12964-024-01699-3.
6
Autophagy-related mechanisms for treatment of multiple myeloma.用于治疗多发性骨髓瘤的自噬相关机制。
Cancer Drug Resist. 2023 Dec 25;6:838-857. doi: 10.20517/cdr.2023.108. eCollection 2023.
7
Shutting off the fuel supply to target metabolic vulnerabilities in multiple myeloma.切断燃料供应以针对多发性骨髓瘤的代谢脆弱点。
Front Oncol. 2023 Jun 8;13:1141851. doi: 10.3389/fonc.2023.1141851. eCollection 2023.
8
Polymorphisms within Autophagy-Related Genes as Susceptibility Biomarkers for Multiple Myeloma: A Meta-Analysis of Three Large Cohorts and Functional Characterization.自噬相关基因多态性作为多发性骨髓瘤易感性生物标志物的研究:三个大队列的荟萃分析及功能特征。
Int J Mol Sci. 2023 May 9;24(10):8500. doi: 10.3390/ijms24108500.
9
TRIM21 enhances bortezomib sensitivity in multiple myeloma by halting prosurvival autophagy.TRIM21 通过阻断生存相关自噬增强多发性骨髓瘤对硼替佐米的敏感性。
Blood Adv. 2023 Oct 10;7(19):5752-5770. doi: 10.1182/bloodadvances.2022008241.
10
Autophagy: A Potential Therapeutic Target to Tackle Drug Resistance in Multiple Myeloma.自噬:一种应对多发性骨髓瘤药物耐药性的潜在治疗靶点。
Int J Mol Sci. 2023 Mar 23;24(7):6019. doi: 10.3390/ijms24076019.